Association of RHAMM with E2F1 promotes tumour cell extravasation by transcriptional up-regulation of fibronectin

Journal of Pathology

Volumn 234, Issue 3, 2014, Pages 351-364

  Meier, Claudia ^a   Spitschak, Alf ^a   Abshagen, Kerstin ^b   Gupta, Shailendra ^c   Mor, Joel M ^d   Wolkenhauer, Olaf ^c   Haier, Jörg ^d   Vollmar, Brigitte ^b   Alla, Vijay ^a   Pützer, Brigitte M ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b Institute of Experimental Surgery Rostock University Medical Centre   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Docking analyses; E2F1 transcription factor; Extravasation; Feed forward loop; Fibronectin; Human tissues; RHAMM

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; HYALURONIC ACID; PROTEIN; RHAMM PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; HERMES ANTIGEN; HYALURONAN-MEDIATED MOTILITY RECEPTOR; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL ACTIVATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXTRAVASATION; LIVER PARENCHYMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN INDUCTION; PROTEIN SECRETION; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHROMATIN IMMUNOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOPRECIPITATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR EMBOLISM; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOPRECIPITATION; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84907942931     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4400     Document Type: Article

References (44)

1. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002; 529:122-125.
2. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13: 11-22.
3. Pützer BM, Engelmann D. E2F1 apoptosis counterattacked: evil strikes back. Trends Mol Med 2013; 19: 89-98.
4. Chen D, Pacal M, Wenzel P, et al. Division and apoptosis of E2F1-deficient retinal progenitors. Nature 2009; 462: 925-929.
5. Alla V, Kowtharapu BS, Engelmann D, et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-3078.
6. Eymin B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-1687.
7. Lee J, Leem S, Lee S, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010; 28: 2660-2667.
8. Alla V, Engelmann D, Niemetz A, et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010; 102: 127-133.
9. Pillai S, Kovacs M, Chellappan S. Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 2010; 70: 4931-4940.
10. Sharma A, Yeow W, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120: 4478-4492.
11. Engelmann D,Mayoli-Nüssle D,Mayrhofer C, et al. E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. J Mol Cell Biol 2013; 53:115-127.
12. Akiyama Y, Jung S, Salhia B, et al. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 2001; 53:115-127.
13. Gust KM, Hofer MD, Perner SR, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009; 11:956-963.
14. Maxwell CA,McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 2008; 121: 925-932.
15. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein andmaintains spindle pole stability. Mol Biol Cell 2003; 14: 2262-2276.
16. Tolg C, Hamilton SR, Morningstar L, et al. RHAMMpromotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 2010; 285: 26461-26474.
17. Engelmann D, Knoll S, Ewerth D, et al. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell Mol Life Sci 2010; 67:931-948.
18. Steder M, Alla V, Meier C, et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell 2013; 24:512-527.
19. John K, Alla V, Meier C, et al. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ 2010; 18: 874-886.
20. Ma C, Wang X. In vitro assays for the extracellular matrix protein-regulated extravasation process. Cold Spring Harbor Protocols 2008; pdb.prot5034.
21. Haier J, Korb T, Hotz B, et al. An intravital model to monitor steps of metastatic tumor cell adhesion within the hepatic microcirculation. J Gastrointest Surg 2003; 7: 507-514.
22. Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234-7242.
23. Silverman-Gavrila R, Silverman-Gavrila L, Hou G, et al. Rear polarization of the microtubule-organizing center in neointimal smooth muscle cells depends on PKCα, ARPC5, and RHAMM. Am J Pathol 2011; 178: 895-910.
24. Tojkander S, Gateva G, Lappalainen P. Actin stress fibers - assembly, dynamics and biological roles. J Cell Sci 2012; 125: 1855-1864.
25. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003; 52: 80-87.
26. Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins 2003; 53: 693-707.
27. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26: 464-469.
28. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
29. Chen MB, Whisler JA, Jeon JS, et al. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr Biol 2013; 5: 1262-1271.
30. Johnson JL, Pillai S, Pernazza D, et al. Regulation of matrix metalloproteinase genes by E2F1transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 2012; 72:516-526.
31. Andrechek ER. HER2/Neu tumorigenesis and metastasis is regulated by E2F1activator transcription factors. Oncogene 2013; DOI:10.1038/onc.2013.540 [Epub ahead of print].
32. Valastyan S,Weinberg RA. Tumor metastasis:molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
33. Lu P,Weaver VM,Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
34. Stanelle J, Stiewe T, Theseling CC, et al. Gene expression changes in response to E2F1 activation. Nucleic Acids Res 2002; 30:1859-1867.
35. Yao ES, Zhang H, Chen Y, et al. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007; 67: 659-664.
36. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial andmesenchymal composition. Science 2013; 339: 580-584.
37. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
38. Ahrens T, Assmann V, Fieber C, et al. CD44 is the principal mediator of hyaluronic acid-induced melanoma cell proliferation. J Invest Dermatol 2001; 116: 93-101.
39. Lee J, Lee J, Farquhar KS, et al. Network of mutually repressive metastasis regulators can promote cell heterogeneity and metastatic transitions. Proc Natl Acad Sci USA 2014; 111: E364-373.
40. Yamasaki C, Tashiro S, Nishito Y, et al. Dynamic cytoplasmic anchoring of the transcription factor Bach1 by intracellular hyaluronic acid binding protein IHABP. J Biochem 2005; 137:287-296.
41. Thomas-Ecker S, Lindecke A, Hatzmann W, et al. Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. Proc Natl Acad Sci USA 2007; 104: 5539-5544.
42. Stoletov K, Kato H, Zardouzian E, et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010; 123: 2332-2341.
43. LiuW, Cheng S, Asa SL, et al. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008; 68: 8104-8112.
44. Twarock S, Tammi MI, Savani RC, et al. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem 2010; 285: 23276-23284.